DGAP-News: STRATEC proposes increased dividend of Euro 0.50 per share
(firmenpresse) - DGAP-News: STRATEC Biomedical Systems AG / Key word(s): Dividend
STRATEC proposes increased dividend of Euro 0.50 per share
28.02.2011 / 15:01
---------------------------------------------------------------------
STRATEC proposes increased dividend of Euro 0.50 per share
Birkenfeld, February 28, 2011
The Supervisory Board and Board of Management of STRATEC Biomedical Systems
AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard, TecDAX) will
propose a dividend of Euro 0.50 per share for the 2010 financial year for
approval by the Company's shareholders at the Annual General Meeting to be
held on April 14, 2011. This proposal represents an increase of 11%
compared with the dividend of Euro 0.45 paid for the previous year.
Hermann Leistner, Chairman of the Board of Management commented 'The 2010
financial year was once again very successful for STRATEC. As well as
acquiring the former Ballista business, now STRATEC Biomedical USA,
specializing in optomechanic system solutions and reader technology,
STRATEC and its subsidiaries also made substantial investments in our
development activities and significantly expanded our production
capacities. While bearing in mind both our future growth strategy and the
need to invest for the long-term, we are delighted to be able to increase
our dividend for the seventh consecutive year'.
Full results for the 2010 financial year and medium-term financial
guidance, based on recent clients' forecasts and statements allied to the
Company's current development pipeline, will be published before the German
market opens on March 8, 2011.
About STRATEC
STRATEC Biomedical Systems AG (www.stratec.com) designs and manufactures
fully automated systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, to laboratories, blood banks and
research institutes around the world. The company develops its products on
the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG as well as subsidiaries and second-tier subsidiaries
in Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
AndréLoy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
ir(at)stratec.com
www.stratec.com
End of Corporate News
---------------------------------------------------------------------
28.02.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info(at)stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
113759 28.02.2011
Datum: 28.02.2011 - 15:01 Uhr
Sprache: Deutsch
News-ID 33323
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 283 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: STRATEC proposes increased dividend of Euro 0.50 per share"
steht unter der journalistisch-redaktionellen Verantwortung von
STRATEC Biomedical Systems AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
